Newsroom

SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced it has secured $36 million in financing led by Catalio Capital Management, a leading innovative healthcare and AI investment firm, with continued support from Baheal, ZAP’s strategic partner in China. The financing reflects strong investor confidence in ZAP’s technology, commercial momentum, and growth potential for non-invasive robotic therapeutics throughout...

SAN JOSE, Calif.--(BUSINESS WIRE)--Zumigo InstaAuth earns FIDO2 Server Certification for phishing-resistant passkey sign-in, paired with carrier-grade phone verification....

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma (ccRCC). The live webcast of the conference call may...

HOUSTON--(BUSINESS WIRE)--NRG Energy, Inc. (NYSE: NRG) today announced that its Board of Directors declared a quarterly dividend on the Company’s common stock of $0.475 per share, or $1.90 per share on an annualized basis. The dividend is payable on November 16, 2026, to stockholders of record as of November 2, 2026. About NRG NRG is a leading provider of electricity, natural gas, and smart home solutions to eight million customers across North America. The company operates a customer-first pla...

BOSTON & WARSAW, Poland & COLOGNE, Germany--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance Announces Entry Into Poland, and Carsten Keune as Country Manager...

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the company will present promising preliminary clinical data from the ongoing Phase 1 portion of its Phase 1/2 PROSPER trial evaluating FMC-376, an equipotent KRAS G12C ON+OFF inhibitor, in patients with advanced KRA...

NORWALK, Conn. & AMSTERDAM & NEW YORK--(BUSINESS WIRE)--Silgan Holdings Inc. (NYSE: SLGN) (“Silgan” or the “Company”), Trivium Packaging B.V. (“Trivium”), and funds affiliated with American Industrial Partners ("AIP") today announced a proposed transaction that will combine Silgan's Metal Containers segment and Food and Beverage Flat Cap Closures businesses with Trivium to create Silgan Metal Containers and Closures (“Silgan MCC”). The combination is a transformational next step that accelerate...

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations or other uncommon EGFR mutations and active central nervous system (CNS) metastases. The data will be...

WOBURN, Mass.--(BUSINESS WIRE)--SES AI Corporation (“SES AI,” the “Company,” “we” or “us”) (NYSE: SES), a global leader in the development and manufacturing of AI-enhanced high-performance Li-Metal and Li-ion batteries, today announced that it has completed the ramp up of its drone battery plant in Chungju, Korea, to an annual production capacity of one million NDAA-compliant cells. Driven by stronger than expected customer demand, the Company plans to immediately begin expanding the plant furt...

NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX, today announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined company will be named “TriGemX Bio, Inc.” (the “Combined Company”...